Case study: complement activation related hypersensitivity reactions to pegylated liposomal doxorubicin - experimental and clinical evidence, mechanisms and approaches to inhibition

Handbook of Immunological Properties of Engineered Nanomaterials: Second Edition

Volumn 2, Issue , 2016, Pages 331-361

  Szebeni, Janos ^a   Muggia, Franco ^b   Barenholz, Yechezkel ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIES; MEDICAL NANOTECHNOLOGY;

CANCER THERAPY; CLINICAL EXPERIENCE; COMPLEMENT ACTIVATIONS; COMPLEMENT SYSTEMS; EXPERIMENTAL ANIMALS; HYPERSENSITIVITY REACTION; LIPOSOMAL DOXORUBICIN; SECRETORY CELLS;

CHEMICAL ACTIVATION;

EID: 85019952245     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9677     Document Type: Chapter

References (112)

1. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation. 1999;99(17):2302-2309. Epub 1999/05/05.
2. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005;216:106-121.
3. EMA. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. 2013.
4. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54(4):987-992. Epub 1994/02/15.
5. Amselem S, Gabizon A, Barenholz Y. Optimization and upscaling of doxorubicincontaining liposomes for clinical use. J Pharm Sci 2006;79:1045-1052.
6. Barenholz Y. Doxil® - The first FDA-approved nano-drug: from an idea to a product. In: Peer D, (Editor). Handbook of Harnessing Biomaterials in Nanomedicine. Singapore: Pan Stanford Publishing; 2012, Chapter 12, pp. 335-397.
7. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992;312(2-3):255-258. Epub 1992/11/09.
8. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982;42(11):4734-4739. Epub 1982/11/01.
9. Gabizon A, Goren D, Fuks Z, Barenholz Y, Dagan A, Meshorer A. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res 1983;43(10):4730-4735. Epub 1983/10/01.
10. Gabizon A, Goren D, Fuks Z, Meshorer A, Barenholz Y. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Brit J Cancer 1985;51(5):681-689. Epub 1985/05/01.
11. Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Ins 1986;77(2):459-469. Epub 1986/08/01.
12. Gabizon A, Goren D, Barenholz Y. Investigations on the antitumor efficacy of liposomeassociated doxorubicin in murine tumor models. Israel J Med Sci 1988;24(9-10):512-517. Epub 1988/09/01.
13. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151(2):201-215. Epub 1993/09/19.
14. Barenholz Y, Haran G. US patent No. 5192549, 1993.
15. Barenholz Y, G. H. Liposomes:efficient loading and controlled release of amphipathic molecules. US Patent No. 5316771, 1994.
16. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987-993.
17. Barenholz Y. Doxil®: The first FDA-approved nanodrug - From an idea to a product In: Bawa R, Audette G, Rubinstein I, (Editors). Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications. Singapore: Pan Stanford Publishing; 2015.
18. Silverman L, Barenholz Y. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site. Nanomed: Nanotechnol Biol Med, 2015; 11(7): 1841-1850, DOI: http://dx.doi. org/10.1016/j.nano.2015.06.007
19. Andriyanov AV, Koren E, Barenholz Y, Goldberg SN. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nanoliposomes. PloS One 2014;9(5):e92555. Epub 2014/05/03.
20. Goldfinger M, Diaz I, Muggia F. Systemic treatment of endometrial cancer: what is doxorubicin's role? J Clin Oncol 2014;32(20):2181-2182. Epub 2014/06/04.
21. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994;33(7):779-786.
22. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13(7):1777-1785.
23. label Db. http://patient.cancerconsultants.com/druginserts/Liposomal_doxorubicin. pdf. 2010.
24. Alving CR, Kinsky SC, Haxby JA, Kinsky CB. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969;8:1582-1587.
25. Kinsky SC, Haxby JA, Zopf DA, Alving CR, Kinsky CB. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969; 8(10):4149-4158.
26. Alving CR, Richards RL, Guirguis AA. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol 1977;118:342-347.
27. Cunningham CM, Kingzette M, Richards RL, Alving CR, Lint TF, Gewurz H. Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol 1979;122(4):1237-1242.
28. Gabizon AA, Muggia FM. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. In: Woodle MC, G. S, (Editors). Long-Circulating Liposomes: Old Drugs, New Therapeutics. Austin, TX: Landes Bioscience; 1998. p. 155-174.
29. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinetics 2003;42:419-436.
30. Szebeni J, Baranyi B, Savay S, Lutz LU, Jelezarova E, Bunger R, et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J Liposome Res 2000;10:347-361.
31. Blume G, Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta 1993;1146(2):157-168. Epub 1993/03/14.
32. Vert M, Domurado D. Poly(ethylene glycol): protein-repulsive or albumin-compatible? J Biomat Sci Polym E 2000;11(12):1307-1317. Epub 2001/03/23.
33. Garbuzenko O, Zalipsky S, Qazen M, Barenholz Y. Electrostatics of PEGylated micelles and liposomes containing charged and neutral lipopolymers. Langmuir 2005;21(6):2560-2568. Epub 2005/03/09.
34. Andresen TL, Jensen SS, Kaasgaard T, Jorgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2005;2(4):353-362. Epub 2005/11/25.
35. Tung HY, Su YC, Chen BM, Burnouf PA, Huang WC, Chuang KH, et al. Selective Delivery of PEGylated compounds to tumor cells by anti-PEG hybrid antibodies. Mol Cancer Ther 2015. Epub 2015/04/09.
36. Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T, Kiwada H, et al. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm 2012;436(1-2):636-643. Epub 2012/08/02.
37. Hashimoto Y, Shimizu T, Mima Y, Abu Lila AS, Ishida T, Kiwada H. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicol Appl Pharm 2014;277(1):30-38. Epub 2014/03/19.
38. Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Controlled Release 2013;172(1):38-47. Epub 2013/08/13.
39. Schellekens H, Hennink WE, Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharmaceut Res. 2013;30(7):1729-1734. Epub 2013/05/16.
40. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Controlled Release 2011;151(2):149-154. Epub 2011/01/13.
41. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Controlled Release 2007; 122(3):349-355. Epub 2007/07/06.
42. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Bio Lett 2005;10(1):37-47. Epub 2005/04/06.
43. Mollnes TE. Therapeutic manipulation of the complement system. In: Szebeni J, editor. The Complement System: Novel Roles in Health and Disease. Boston: Kluwer; 2004. p. 483-516.
44. Szebeni J, editor. The Complement System: Novel Roles in Health and Disease. Boston: Kluwer; 2004.
45. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol 1999;19:173-198.
46. Doxil®. Doxil® package insert 2012. http://wwwDoxil®com/assets/DOXIL®_PI_ Bookletpdf. 2012;http://www.Doxil®.com.
47. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1(3):297-315. Epub 2007/08/28.
48. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1993;1179(2):157-165. Epub 1993/11/07.
49. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 2001;1513(1):25-37. Epub 2001/06/28.
50. Dierich MP. The Receptors. In: Rother K, Till GO (Editors). The Complement System. Springer-Verlag, Berlin, 1988. p. 262-272.
51. Szebeni J, Weiszhár Z, Rozsnyay Z, Martinsky T, Kádas J, Lázár J, et al. Plasma Proteome Profiling with Monoclonal Antibody Libraries: A Pilot Biomarker Analysis for Nanomedicine-Induced Complement Activation. 2013.
52. Pouw RB, Vredevoogd DW, Kuijpers TW, Wouters D. Of mice and men: The factor H protein family and complement regulation. Mol Immunol 2015. Epub 2015/04/01.
53. Fülöp TG, Józsi M, Metselaar J, Storm G, Rosivall L, Szebeni J. The possible role of factor H in complement activation-related pseudoallergy (CARPA): a failed attempt to correlate blood levels of FH with liposome-induced hypersensitivity reactions in patients with autoimmune disease. Eur J Nanomedicine 2015;7(1):7-14.
54. Lieberman P. Anaphylactoid reactions to radiocontrast materia. Clin Rev Allergy 1991;9:319-338.
55. Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. Singapore Med J 1989;30:290-293.
56. Takeda K, Thurman JM, Tomlinson S, Okamoto M, Shiraishi Y, Ferreira VP, et al. The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol 2012;188:661-667.
57. Roerdink F, Wassef NM, Richardson EC, Alving CR. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. Biochim Biophys Acta 1983;734(1):33-39.
58. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991;146:4234-4241.
59. Sloan S, Nishiya T. Interaction of liposomes with erythrocytes or platelets, effect of liposome surface charges and RGD ligand. Artif Cells Blood Subst Immob Biotechnol 1996;24:431.
60. Bradley AJ, Brooks DE, Norris-Jonesa R, Devinea DV. C1q Binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. Biochim Biophys Acta. 1999;1418: 19-30.
61. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Controlled Release 1999;61(1-2):233-240.
62. Richards RL, Habbersett RC, Scher I, Janoff AS, Schieren HP, Mayer LD, et al. Influence of vesicle size on complement-dependent immune damage to liposomes. Biochim Biophys Acta. 1986;855(2):223-230.
63. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharmace Res. 1994;11(3):402-406.
64. Szebeni J, Baranyi L, Savay S, Bodo M, Morse DS, Basta M, et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physio-Heart Circul Physio. 2000;279(3):H1319-H1328.
65. Neun BW, Dobrovolskaia MA. Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays. Meth Mol Biol 2011;697:121-130. Epub 2010/12/01.
66. Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE. Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (Lond) 2010;5(4):555-562. Epub 2010/06/10.
67. Dobrovolskaia MA, Neun BW, Clogston JD, Grossman JH, McNeil SE. Choice of method for endotoxin detection depends on nanoformulation. Nanomedicine (Lond) 2014;9(12):1847-56. Epub 2013/12/24.
68. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhár Z, Urbanics R, Rosivall L, et al. Liposomeinduced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil® and AmBisome. Nanomedicine NBM 2012;8:176-184.
69. Milosevits G, Rozsnyay Z, Kozma GT, Milosevits J, Tömöry G, Robotka H, et al. Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes. Chem Phys Lipids 2012;165:482-487.
70. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011;63(12):1020-1030. Epub 2011/07/27.
71. Baranyi L, Szebeni J, Savay S, Bodo M, Basta M, Bentley TB, et al. Complementdependent shock and tissue damage induced by intravenous injection of cholesterolenriched liposomes in rats. J Appl Res 2003;3(3).
72. Moghimi SM, Hamad I, Andresen TL, Jörgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006;20:2591-2593.
73. Romberg B, Baranyi L, Bünger R, Hennink W-E, Szebeni J, Storm G. Initial observations on complement activation by poly(amino acid)-coated liposomes. In: Romberg B, editor. Poly(amino acid)s: next-generation coatings for long-circulating liposomes. PhD thesis. Utrecht: Utrecht University; 2007.
74. Romberg B, Metselaar JM, Baranyi L, Snel CJ, Bunger R, Hennink WE, et al. Poly(amino acid)s: Promising enzymatically degradable stealth coatings for liposomes. Int J Pharm 2007;331:186-189.
75. Strejan GH, Smith PM, Grant CW, Surlan D. Naturally occurring antibodies to liposomes. I. Rabbit antibodies to sphingomyelin-containing liposomes before and after immunization with unrelated antigens. J Immunol 1979;123:370-378.
76. Strejan GH, Essani K, Surlan D. Naturally occurring antibodies to liposomes. II. Specificity and electrophoretic pattern of rabbit antibodies reacting with sphingomyelincontaining liposomes. J Immunol 1981;127:160-165.
77. Alving CR. Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans 1984;12:342-344.
78. Wassef NM, Johnson SH, Graeber GM, Swartz GM, Jr., Schultz CL, Hailey JR, et al. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol 1989;143(9):2990-5. Epub 1989/11/01.
79. Coune A, Sculier JP, Frühling J, Stryckmans P, Brassine C, Ghanem G, et al. IV administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man. Cancer Treat Rep 1983;67:1031-1033.
80. Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil®). Anti-Cancer Drugs 1998;9(1):45-50. Epub 1998/03/10.
81. Cheung AK, Parker CJ, Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994;46(6):1680-1687. Epub 1994/12/01.
82. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artif Organs 1994;18(12):880-887. Epub 1994/12/01.
83. Skroeder NR, Kjellstrand P, Holmquist B, Kjellstrand CM, Jacobson SH. Individual differences in biocompatibility responses to hemodialysis. Int J Artif Organs 1994;17(10):521-530. Epub 1994/10/01.
84. Brouwers AH, De Jong DJ, Dams ET, Oyen WJ, Boerman OC, Laverman P, et al. Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease. J Drug Target 2000;8(4):225-233. Epub 2001/01/06.
85. Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, et al. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000;41(4):622-630. Epub 2000/04/18.
86. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions. Ann Oncol 2003;14(9):1430-1437. Epub 2003/09/05.
87. Szebeni J, Bedocs P, Urbanics R, Bunger R, Rosivall L, Tóth M, et al. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Controlled Release 2012;160:382-387.
88. Szebeni J, Baranyi L, Savay S, Bodo M, Milosevits J, Alving CR, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physio-Heart Circul Physio. 2006;290(3):H1050-H1058.
89. Szebeni J. Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 2014;61:163-173.
90. Szebeni J, Bedocs P, Csukas D, Rosivall L, Bunger R, Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev 2012;64(15):1706-1716. Epub 2012/07/24.
91. Dézsi L, Fülöp T, Mészáros T, Szénási G, Urbanics R, Vázsonyi C, et al. Features of Complement Activation-Related Pseudoallergy to Liposomes with Different Surface Charge and PEGylation: Comparison of the Porcine and Rat Responses. J Controlled Release 2014; 195: 2-10.
92. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immun 1984;7(2-3):193-219. Epub 1984/01/01.
93. Hugli TE. Biochemistry and biology of anaphylatoxins. Complement 1986;3(3):111-127. Epub 1986/01/01.
94. Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, et al. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011;122(2):226-232. Epub 2011/05/18.
95. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32(13):1302-1308. Epub 2014/03/19.
96. Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxaneresistant ovarian cancer. Ann Oncol 2012;23(12):3104-3110. Epub 2012/08/02.
97. Zhao Y, Wang L, Yan M, Ma Y, Zang G, She Z, et al. Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. Int J Nanomedicine 2012;7:2891-2900.
98. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharmaceut Res 2009;10:2270-2979.
99. Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm 2008;362:197-200.
100. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008;354:56-62.
101. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Controlled Release 2006;115:243-250.
102. Wang XY, Ishida T, Ichihara M, Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Controlled Release 2005;104.
103. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Controlled Release 2005;105:305-317.
104. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharm Ex Therapeu. 2000;292:1071-1079.
105. Kozma G, Mészáros T, Weiszhár Zs, Schneider T, Rosta A, Urbanics R, et al., Variable association of complement activation by rituximab and paclitaxel in cancer patients in vivo and in their screening serum in vitro with clinical manifestations of hypersensitivity: a pilot study. Eur J Nanomed. 2015; 7(4): 289-302.
106. Demoly P, Lebel B, Messaad D, Sahla H, Rongier M, Daures JP, et al. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 1999;54:500-506.
107. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy 1999;54:999-1003.
108. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
109. Adkinson NFJ, Essayan D, Gruchalla R, Haggerty H, Kawabata T, Sandler JD, et al. Task force report: future research needs for the prevention and management of immunemediated drug hypersensitivity reactions. J Allergy Clin Immunol 2002;109:S461-S478.
110. Szebeni J. Complement Activation: A Capricious Immune Barrier to the Clinical Use of Nanomedicines. In: Bawa R, Audette G, Rubinstein I, (Editors). Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications. Singapore: Pan Stanford Publishing; 2015, in press.
111. Barenholz Y. Doxil®: The First FDA-Approved Nanodrug - From an Idea to a Product. In: Bawa, R., Audette, G. and Rubinstein, I. (Editors). Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications, Singapore, Pan Stanford Publishing; 2015, in press.
112. Barenholz Y. (2012). Doxil - The first FDA approved nano-drug: Lessons learned. J Controlled Release 2012; 160(2):117-134